MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 207 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,967,048 | -32.0% | 40,859 | +7.5% | 1.59% | -9.9% |
Q2 2023 | $8,780,541 | +0.6% | 38,011 | +5.5% | 1.77% | -22.0% |
Q1 2023 | $8,730,566 | +12.4% | 36,038 | +34.6% | 2.27% | +12.5% |
Q4 2022 | $7,770,863 | +167.2% | 26,773 | -40.2% | 2.02% | +192.6% |
Q3 2022 | $2,908,000 | -9.7% | 44,747 | -0.6% | 0.69% | -23.0% |
Q2 2022 | $3,221,000 | – | 45,000 | – | 0.90% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |